Doctor Bio:
Dr. Matthew J. Frigault is an Instructor at Harvard Medical School and Clinical Director of the Cellular Immunotherapy Program, BMT Cellular Therapy at Massachusetts General Hospital in Boston, MA.
Phase 1 Study of CAR T-ddBCMA in RRMM Presented at ASCO 2022
Dr. Matthew J. Frigault Discusses the Phase 1 Study of CAR T-ddBCMA in RRMM Patients
In this video:
Dr. Matthew J. Frigault (Harvard Medical School, Massachusetts General Hospital—Boston, MA) discusses the Phase 1 Study of CAR T-ddBCMA in relapsed/refractory myeloma patients.
What is the purpose of this trial?
Chimeric Antigen Receptor (CAR) T cell therapies targeting B-cell maturation antigen (BCMA) have demonstrated benefit in patients (pts) with relapsed and/or refractory Multiple Myeloma (RRMM). CART-ddBCMA is an autologous anti-BCMA CAR T cell therapy that utilizes a novel, synthetic binding domain, called a D-Domain, instead of a typical scFv binder. The objective of this first-in-human trial is to assess the safety and efficacy of CART-ddBCMA.
Conclusion:
To date, CAR T-ddBCMA administration has demonstrated clinical activity, including 100% overall response rate (ORR) with rates of complete response (CR)/stringent complete response (sCR) and ≥ very good partial response (VGPR) of 67% and 88%, respectively. Durable responses beyond 18 months have been observed, including in patients with extramedullary disease (EMD).
Clinical trial information: NCT04155749
with support from:
Bristol Myers Squibb, Janssen, and Takeda Oncology
